Patents by Inventor Koen Kas

Koen Kas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190382823
    Abstract: The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.
    Type: Application
    Filed: May 8, 2019
    Publication date: December 19, 2019
    Inventors: Clive Gavin Brown, Koen Kas, Sven Agnes Jan Eyckerman
  • Patent number: 10316349
    Abstract: The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 11, 2019
    Assignee: Caris Science, Inc.
    Inventors: Clive Gavin Brown, Koen Kas, Sven Agnes Jan Eyckerman
  • Patent number: 10114021
    Abstract: The application discloses Quiescin Q6 as a new biomarker for acute heart failure. Methods for determining the quantity of Quiescin Q6 in a sample from a subject are described. The quantity of Quiescin Q6 is determined by contacting the sample with one or more binding agents capable of specifically binding to Quiescin Q6.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: October 30, 2018
    Assignee: MYCARTIS NV
    Inventor: Koen Kas
  • Patent number: 9915666
    Abstract: The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: March 13, 2018
    Assignee: MYCARTIS NV
    Inventor: Koen Kas
  • Publication number: 20180030505
    Abstract: The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.
    Type: Application
    Filed: August 4, 2017
    Publication date: February 1, 2018
    Applicant: Caris Life Sciences Switzerland Holdings GmbH
    Inventors: Clive Gavin BROWN, Koen KAS, Sven Agnes Jan EYCKERMAN
  • Patent number: 9791457
    Abstract: The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: October 17, 2017
    Assignee: MYCARTIS NV
    Inventor: Koen Kas
  • Patent number: 9758811
    Abstract: The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: September 12, 2017
    Assignee: Caris Life Sciences Switzerland Holdings GmbH
    Inventors: Clive Gavin Brown, Koen Kas, Sven Agnes Jan Eyckerman
  • Patent number: 9638701
    Abstract: A method is described for treating a subject having acute heart failure (AHF) by measuring PERLECAN levels in the subject. The PERLECAN level in the subject is used to determine risk of mortality within one year for the subject. Treatment is selected on the basis of the outcome of the assay.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 2, 2017
    Assignee: MYCARTIS NV
    Inventors: Koen Kas, Griet Vanpoucke, Piet Moerman
  • Publication number: 20170010265
    Abstract: The application discloses Quiescin Q6 as a new biomarker for acute heart failure. Methods for determining the quantity of Quiescin Q6 in a sample from a subject are described. The quantity of Quiescin Q6 is determined by contacting the sample with one or more binding agents capable of specifically binding to Quiescin Q6.
    Type: Application
    Filed: August 19, 2016
    Publication date: January 12, 2017
    Inventor: Koen Kas
  • Patent number: 9465039
    Abstract: The application discloses PERLECAN as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 11, 2016
    Assignee: MYCARTIS NV
    Inventors: Koen Kas, Griet Vanpoucke, Piet Moerman
  • Publication number: 20160245826
    Abstract: The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring the dysfunction based on measuring the biomarker and kits and devices for measuring the biomarker and/or preforming the methods.
    Type: Application
    Filed: March 1, 2016
    Publication date: August 25, 2016
    Inventor: Koen Kas
  • Publication number: 20160054330
    Abstract: The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: November 3, 2015
    Publication date: February 25, 2016
    Inventor: Koen Kas
  • Publication number: 20160047817
    Abstract: The application discloses methods for treating a subject presenting with one or more signs of an inflammatory condition, or methods for evaluating the risk of death within a year for a subject presenting with one or more signs of an inflammatory condition, based on measuring the quantity of LTBP2 in a sample from the subject; and kits and devices for measuring LTBP2 and/or performing said methods.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 18, 2016
    Inventor: Koen Kas
  • Publication number: 20160047822
    Abstract: The application discloses MCAM as a new biomarker for acute heart failure; methods for predicting, diagnosing, prognosticating and/or monitoring acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: November 2, 2015
    Publication date: February 18, 2016
    Inventor: Koen Kas
  • Publication number: 20150330995
    Abstract: The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: August 5, 2015
    Publication date: November 19, 2015
    Inventor: Koen Kas
  • Publication number: 20150293124
    Abstract: A method is described for treating a subject having acute heart failure (AHF) by measuring PERLECAN levels in the subject. The PERLECAN level in the subject is used to determine risk of mortality within one year for the subject. Treatment is selected on the basis of the outcome of the assay.
    Type: Application
    Filed: June 25, 2015
    Publication date: October 15, 2015
    Inventors: Koen Kas, Griet Vanpoucke, Piet Moerman
  • Publication number: 20150087536
    Abstract: The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 26, 2015
    Applicant: Caris Life Sciences Switzerland Holdings GmbH
    Inventors: Clive Gavin BROWN, Koen KAS, Sven Agnes Jan EYCKERMAN
  • Publication number: 20140302509
    Abstract: The present invention relates to procathepsin L, cathepsin L or a fragment thereof as a biomarker for ischemia. The present invention further relates to methods for diagnosing, predicting, prognosticating and/or monitoring ischemia based on measuring said biomarker, and to related kits, devices and uses thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: October 9, 2014
    Inventors: Piet Moerman, Griet Vanpoucke, Gregoire Thomas, Koen Kas
  • Publication number: 20140236833
    Abstract: The current invention relates to a method for establishing a transaction between an individual and a third party, based on the genetic identity of an individual, characterized in that said individual allows third party to access and analyze only a subset of said genetic identity, required for the offer and establishment of the transaction. In a second aspect, the invention discloses tools for the analysis of the genetic identity of individuals.
    Type: Application
    Filed: October 5, 2012
    Publication date: August 21, 2014
    Inventor: Koen KAS
  • Publication number: 20140113308
    Abstract: The application discloses MCAM as a new biomarker for fluid homeostatic imbalance; methods for predicting, diagnosing, prognosticating and/or monitoring fluid homeostatic imbalance based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.
    Type: Application
    Filed: December 5, 2013
    Publication date: April 24, 2014
    Applicant: PRONOTA N.V.
    Inventor: Koen Kas